Introduction:
Switzerland-based LimmaTech Biologics has acquired an exclusive license option from AbVacc Inc to co-develop a preclinical Staphylococcus aureus vaccine called LBT-SA7. The agreement allows LimmaTech to conduct Phase I clinical trials with the vaccine, which is designed to prevent hospital-acquired infections with the multidrug-resistant bacterium. If Phase I is successful, LimmaTech has the option to acquire full worldwide rights to the vaccine.
- LimmaTech Biologics and AbVacc Inc have agreed to co-develop a preclinical Staphylococcus aureus vaccine called LBT-SA7.
- The vaccine is aimed at preventing hospital-acquired infections with the multidrug-resistant bacterium.
- LimmaTech has exclusive rights to conduct Phase I clinical trials with the vaccine.
- The vaccine consists of five components representing toxoids for seven Staphylococcus aureus toxins.
- LBT-SA7 has shown efficacy in various animal models for the prevention of recurrent skin and soft tissue infections caused by Staphylococcus aureus.
Conclusion:
This partnership between LimmaTech Biologics and AbVacc Inc aims to develop a vaccine that can prevent hospital-acquired infections caused by Staphylococcus aureus, a multidrug-resistant bacterium. The vaccine, LBT-SA7, has shown promising results in preclinical studies, and LimmaTech will now conduct Phase I clinical trials to further assess its safety and efficacy. The successful development and commercialization of this vaccine could provide a valuable tool in the fight against antimicrobial infections.
